ES2974252T3 - Proteínas bifuncionales que combinan bloqueo de puntos de control para terapia dirigida - Google Patents
Proteínas bifuncionales que combinan bloqueo de puntos de control para terapia dirigidaInfo
- Publication number
- ES2974252T3 ES2974252T3 ES19759945T ES19759945T ES2974252T3 ES 2974252 T3 ES2974252 T3 ES 2974252T3 ES 19759945 T ES19759945 T ES 19759945T ES 19759945 T ES19759945 T ES 19759945T ES 2974252 T3 ES2974252 T3 ES 2974252T3
- Authority
- ES
- Spain
- Prior art keywords
- targeted therapy
- checkpoint blockade
- bifunctional proteins
- proteins combining
- combining checkpoint
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Active
Links
- 230000001588 bifunctional effect Effects 0.000 title 1
- 230000005746 immune checkpoint blockade Effects 0.000 title 1
- 102000004169 proteins and genes Human genes 0.000 title 1
- 108090000623 proteins and genes Proteins 0.000 title 1
- 238000002626 targeted therapy Methods 0.000 title 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
- C07K14/70578—NGF-receptor/TNF-receptor superfamily, e.g. CD27, CD30, CD40, CD95
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
- C07K14/70596—Molecules with a "CD"-designation not provided for elsewhere
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
- C07K14/71—Receptors; Cell surface antigens; Cell surface determinants for growth factors; for growth regulators
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
- C07K14/72—Receptors; Cell surface antigens; Cell surface determinants for hormones
- C07K14/723—G protein coupled receptor, e.g. TSHR-thyrotropin-receptor, LH/hCG receptor, FSH receptor
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/22—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against growth factors ; against growth regulators
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/2803—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
- C07K16/2827—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily against B7 molecules, e.g. CD80, CD86
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
- G01N33/574—Immunoassay; Biospecific binding assay; Materials therefor for cancer
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
- G01N33/574—Immunoassay; Biospecific binding assay; Materials therefor for cancer
- G01N33/57407—Specifically defined cancers
- G01N33/57434—Specifically defined cancers of prostate
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
- C07K2317/21—Immunoglobulins specific features characterized by taxonomic origin from primates, e.g. man
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
- C07K2317/31—Immunoglobulins specific features characterized by aspects of specificity or valency multispecific
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/52—Constant or Fc region; Isotype
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/55—Fab or Fab'
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
- C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
- C07K2317/732—Antibody-dependent cellular cytotoxicity [ADCC]
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
- C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2319/00—Fusion polypeptide
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
- G01N2333/435—Assays involving biological materials from specific organisms or of a specific nature from animals; from humans
- G01N2333/475—Assays involving growth factors
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
- G01N2333/435—Assays involving biological materials from specific organisms or of a specific nature from animals; from humans
- G01N2333/705—Assays involving receptors, cell surface antigens or cell surface determinants
- G01N2333/70596—Molecules with a "CD"-designation not provided for elsewhere in G01N2333/705
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Immunology (AREA)
- Organic Chemistry (AREA)
- Medicinal Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Molecular Biology (AREA)
- Biochemistry (AREA)
- Engineering & Computer Science (AREA)
- Biophysics (AREA)
- Cell Biology (AREA)
- Genetics & Genomics (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Gastroenterology & Hepatology (AREA)
- Zoology (AREA)
- Toxicology (AREA)
- Hematology (AREA)
- Urology & Nephrology (AREA)
- Biomedical Technology (AREA)
- Microbiology (AREA)
- Veterinary Medicine (AREA)
- Pharmacology & Pharmacy (AREA)
- Public Health (AREA)
- Animal Behavior & Ethology (AREA)
- Biotechnology (AREA)
- Hospice & Palliative Care (AREA)
- Food Science & Technology (AREA)
- Physics & Mathematics (AREA)
- Analytical Chemistry (AREA)
- General Physics & Mathematics (AREA)
- Pathology (AREA)
- Oncology (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Epidemiology (AREA)
- Endocrinology (AREA)
- Mycology (AREA)
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US201862636825P | 2018-02-28 | 2018-02-28 | |
PCT/US2019/019786 WO2019168947A1 (en) | 2018-02-28 | 2019-02-27 | Bifunctional proteins combining checkpoint blockade for targeted therapy |
Publications (1)
Publication Number | Publication Date |
---|---|
ES2974252T3 true ES2974252T3 (es) | 2024-06-26 |
Family
ID=67806427
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
ES19759945T Active ES2974252T3 (es) | 2018-02-28 | 2019-02-27 | Proteínas bifuncionales que combinan bloqueo de puntos de control para terapia dirigida |
Country Status (13)
Country | Link |
---|---|
US (2) | US11780922B2 (es) |
EP (1) | EP3758735B1 (es) |
JP (1) | JP7464525B2 (es) |
KR (1) | KR102469248B1 (es) |
CN (1) | CN111565738B (es) |
AU (1) | AU2019227715B2 (es) |
BR (1) | BR112020013854A2 (es) |
CA (1) | CA3085467A1 (es) |
ES (1) | ES2974252T3 (es) |
RU (1) | RU2756899C1 (es) |
SG (1) | SG11202005290QA (es) |
TW (1) | TWI731310B (es) |
WO (1) | WO2019168947A1 (es) |
Families Citing this family (7)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
RU2494108C2 (ru) | 2006-04-07 | 2013-09-27 | Аерпио Терапетикс, Инк. | Антитела, которые связывают человеческий белок бета-тирозин фосфатазу (нртрвета), и их использование |
EP4268848A3 (en) * | 2017-12-29 | 2024-01-10 | AP Biosciences, Inc. | Monospecific and bispecific proteins with immune checkpoint regulation for cancer therapy |
CN113164597A (zh) | 2018-09-24 | 2021-07-23 | 爱尔皮奥制药公司 | 靶向HPTP-β(VE-PTP)和VEGF的多特异性抗体 |
EP3891182A4 (en) * | 2018-12-03 | 2022-08-17 | Immuneonco Biopharmaceuticals (Shanghai) Co., Ltd | RECOMBINATION PROTEIN TARGETING PD-L1 AND VEGF |
WO2021147829A1 (en) * | 2020-01-21 | 2021-07-29 | Wuxi Biologics (Shanghai) Co. Ltd. | A bispecific anti-pd-l1/vegf antibody and uses thereof |
CN113754776A (zh) * | 2020-06-02 | 2021-12-07 | 三生国健药业(上海)股份有限公司 | 一种抗pd-l1/vegf融合蛋白 |
WO2024032662A1 (zh) * | 2022-08-09 | 2024-02-15 | 上海济煜医药科技有限公司 | 一种靶向pd-1和vegf的抗体及其应用 |
Family Cites Families (25)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US20080254512A1 (en) * | 2006-11-02 | 2008-10-16 | Capon Daniel J | Hybrid immunoglobulins with moving parts |
KR101397088B1 (ko) * | 2011-06-10 | 2014-05-19 | 강원대학교산학협력단 | 암세포 증식 억제와 혈관신생 억제를 위한 융합 단백질 및 이를 포함한 항암 조성물 |
EP2855528B1 (en) * | 2012-05-31 | 2019-06-19 | Genentech, Inc. | Methods of treating cancer using pd-l1 axis binding antagonists and vegf antagonists |
KR20220084444A (ko) * | 2012-05-31 | 2022-06-21 | 소렌토 쎄라퓨틱스, 인코포레이티드 | Pd-l1에 결합하는 항원 결합 단백질 |
KR20150036606A (ko) * | 2012-07-13 | 2015-04-07 | 자임워크스 인코포레이티드 | 항-cd3 구조체를 포함하는 이중특이적 비대칭 이형이합체 |
KR102049990B1 (ko) | 2013-03-28 | 2019-12-03 | 삼성전자주식회사 | c-Met 항체 및 VEGF 결합 단편이 연결된 융합 단백질 |
EP3293275B1 (en) * | 2013-06-06 | 2021-08-04 | Dana-Farber Cancer Institute, Inc. | Compositions and methods for identification, assessment prevention, and treatment of cancer using pd-l1 isoforms |
CN104341504B (zh) * | 2013-08-06 | 2017-10-24 | 百奥泰生物科技(广州)有限公司 | 双特异性抗体 |
EP3065772A4 (en) | 2013-11-05 | 2017-09-13 | Cognate Bioservices, Inc. | Combinations of checkpoint inhibitors and therapeutics to treat cancer |
TWI681969B (zh) | 2014-01-23 | 2020-01-11 | 美商再生元醫藥公司 | 針對pd-1的人類抗體 |
JP6355032B2 (ja) | 2014-03-24 | 2018-07-11 | イミューンオンコ バイオファーマシューティカルズ (シャンハイ) カンパニー リミテッド | 新規組換え二機能性融合タンパク質、それらの調製および使用 |
CA2953807A1 (en) | 2014-06-26 | 2015-12-30 | Yale University | Compositions and methods to regulate renalase in the treatment of diseases and disorders |
AU2015357543B2 (en) * | 2014-12-05 | 2021-10-21 | Eureka Therapeutics, Inc. | Chimeric antigen receptors targeting Fc Receptor-like 5 and uses thereof |
TWI595006B (zh) | 2014-12-09 | 2017-08-11 | 禮納特神經系統科學公司 | 抗pd-1抗體類和使用彼等之方法 |
SG11201705271YA (en) * | 2015-03-11 | 2017-07-28 | Allgenesis Biotherapeutics Inc | Fusion protein comprising a ligand binding domain of vegf and pdgf |
WO2017031157A1 (en) | 2015-08-18 | 2017-02-23 | Mateon Therapeutics, Inc. | Use of vdas to enhance immunomodulating therapies against tumors |
EP3377112A4 (en) * | 2015-11-18 | 2019-06-12 | Sorrento Therapeutics, Inc. | CHEMICALLY BLOCKED BISPECIFIC ANTIBODIES |
EP3411068A4 (en) * | 2016-02-02 | 2020-01-29 | Kadmon Corporation, LLC | BISPECIFIC BINDING PROTEINS FOR PD-L1 AND KDR |
CN109311995A (zh) * | 2016-03-29 | 2019-02-05 | 台湾浩鼎生技股份有限公司 | 抗体、药物组合物和方法 |
AU2017248766A1 (en) | 2016-04-15 | 2018-11-01 | Genentech, Inc. | Methods for monitoring and treating cancer |
WO2017200173A1 (ko) * | 2016-05-19 | 2017-11-23 | 삼성전자 주식회사 | Vegf 결합 단편 변이체 및 상기 vegf 결합 단편 변이체 및 항 c-met 항체를 포함하는 융합 단백질 |
CA3027209C (en) | 2016-06-13 | 2022-08-16 | I-Mab | Anti-pd-l1 antibodies and uses thereof |
CN107602702A (zh) | 2017-09-22 | 2018-01-19 | 生标(上海)医疗器械科技有限公司 | 一种同时靶向人p185和血管内皮生长因子的抗体及其应用 |
CN109575140B (zh) * | 2017-09-29 | 2021-02-23 | 北京比洋生物技术有限公司 | 靶向pd-1或pd-l1且靶向vegf家族的双靶向融合蛋白及其用途 |
EP4268848A3 (en) * | 2017-12-29 | 2024-01-10 | AP Biosciences, Inc. | Monospecific and bispecific proteins with immune checkpoint regulation for cancer therapy |
-
2019
- 2019-02-27 EP EP19759945.9A patent/EP3758735B1/en active Active
- 2019-02-27 KR KR1020207018170A patent/KR102469248B1/ko active IP Right Grant
- 2019-02-27 ES ES19759945T patent/ES2974252T3/es active Active
- 2019-02-27 WO PCT/US2019/019786 patent/WO2019168947A1/en unknown
- 2019-02-27 RU RU2020125987A patent/RU2756899C1/ru active
- 2019-02-27 AU AU2019227715A patent/AU2019227715B2/en active Active
- 2019-02-27 CA CA3085467A patent/CA3085467A1/en active Pending
- 2019-02-27 JP JP2020540311A patent/JP7464525B2/ja active Active
- 2019-02-27 CN CN201980007127.7A patent/CN111565738B/zh active Active
- 2019-02-27 SG SG11202005290QA patent/SG11202005290QA/en unknown
- 2019-02-27 BR BR112020013854-1A patent/BR112020013854A2/pt not_active Application Discontinuation
- 2019-02-27 TW TW108106894A patent/TWI731310B/zh active
-
2020
- 2020-06-09 US US16/896,597 patent/US11780922B2/en active Active
-
2023
- 2023-06-26 US US18/214,160 patent/US20230322931A1/en active Pending
Also Published As
Publication number | Publication date |
---|---|
BR112020013854A2 (pt) | 2020-12-01 |
CA3085467A1 (en) | 2019-09-06 |
US20200299389A1 (en) | 2020-09-24 |
KR102469248B1 (ko) | 2022-11-22 |
US11780922B2 (en) | 2023-10-10 |
TW201945023A (zh) | 2019-12-01 |
RU2756899C1 (ru) | 2021-10-06 |
EP3758735A4 (en) | 2021-12-08 |
WO2019168947A1 (en) | 2019-09-06 |
CN111565738B (zh) | 2023-12-26 |
AU2019227715B2 (en) | 2022-03-31 |
TWI731310B (zh) | 2021-06-21 |
EP3758735A1 (en) | 2021-01-06 |
JP2021511786A (ja) | 2021-05-13 |
AU2019227715A1 (en) | 2020-06-18 |
WO2019168947A8 (en) | 2019-10-03 |
US20230322931A1 (en) | 2023-10-12 |
KR20200088883A (ko) | 2020-07-23 |
NZ765074A (en) | 2023-11-24 |
SG11202005290QA (en) | 2020-07-29 |
JP7464525B2 (ja) | 2024-04-09 |
EP3758735B1 (en) | 2023-12-13 |
CN111565738A (zh) | 2020-08-21 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
ES2974252T3 (es) | Proteínas bifuncionales que combinan bloqueo de puntos de control para terapia dirigida | |
CY1122981T1 (el) | Συνθεσεις για διαμορφωση της εκφρασης του c9orf72 | |
BR112018071307A2 (pt) | anticorpos agonistas que ligam cd40 humana e usos dos mesmos | |
BR112018002432A2 (pt) | anticorpos de ligação à il-8 e usos dos mesmos | |
IL265274A (en) | Combined treatment of antibody and checkpoint inhibitor | |
MA43037A (fr) | Polythérapie par inhibiteurs de bromodomaine et blocage de point de contrôle | |
ECSP17034845A (es) | Conjugados de anticuerpo- farmaco | |
DK3740504T3 (da) | CD70 kombinationsterapi | |
BR112017017927A2 (pt) | receptores quiméricos de antígenos anti-dll3 e métodos de uso | |
ES2974281T3 (es) | Composiciones farmacéuticas para terapia de combinación | |
CL2018000946A1 (es) | Proteínas de unión a antigeno que activan el receptor de leptina | |
BR112017012954A2 (pt) | composições e métodos para anticorpos que têm como alvo a bmp6 | |
BR112019005139A2 (pt) | anticorpos anti-il-33 e usos dos mesmos | |
MA53887A (fr) | Anticorps à liaison protofibrille a-bêta améliorée | |
DK3782571T3 (da) | Lasersystem til vævsterapi med flere stråler | |
DK3500241T3 (da) | Kombinationsterapi til kol | |
DK3870578T3 (da) | Terapeutiske forbindelser | |
DK3362569T3 (da) | Cxcr6-transducerede t-celler til målrettet tumorterapi | |
DK3488443T3 (da) | Udvælgelse af neoepitoper som sygdomsspecifikke mål for terapi med øget virkning | |
ES2721935T3 (es) | Anticuerpos anti-BAG3 para uso terapéutico | |
ES2681118B1 (es) | Dispositivo de inmovilización para radioterapia | |
BR112017017883A2 (pt) | doses e métodos para administrar telavancina | |
DK3538029T3 (da) | Ledimplantat til vævsnydannelse på leddet | |
DK3573713T3 (da) | Fodtøj til magnetterapi | |
BR112015022576A2 (pt) | produto farmacêutico e seu uso, kit e método para tratar uma disfunção hiperproliferativa |